Company profile
UK company 11106423, incorporated on 11 December 2017.
Flexible automation for protein analysis
Biological sensors for rapid and cost-effective detection of biological substances like proteins, DNA or small molecules. This award-winning technology eliminates the need for lengthy and expensive lab processes.
Company number 11106423
Reference milestones and recent Companies House filing stream events.
Company registered at Companies House
It is our mission to design novel nanomaterials for innovative future applications in biotechnology, sensing and quantum computing. Our technology is scalable and sustainable. At HexagonFab, we bring these materials from the laboratory to the market. By scaling to the nanoscale, we not only reduce material input, but also enable novel technologies. New material properties open the door to new application that have so far been unmet with conventional material approaches. Our material will enable affordable, ultrasensitive point of care bio-sensors, advanced photo-detectors and controlled single photon emitters for quantum computing. We offer individual 2D materials like graphene and hexagonal boron nitride (h-BN). But going a step further, we are the world's first company to offer vertical stacks of 2D materials, commonly known as van der Waals (vdW) heterostructures, on an industrial scale. Our advanced process technology allows the assembly of 2D materials with atomic precision layer by layer. We can engineer material properties at unprecedented level for your specific requirements.
2 paying customers within first months of incorperation.
1 Jan 2025 to 31 Mar 2025
Herceptin, also known as Trastuzumab, is a pioneering antibody drug used in the treatment of HER2-positive breast cancer. By targeting the HER2 protein abundantly expressed on the surface of certain breast cancer cells, Herceptin serves as a beacon, marking these cells for immune system recognition and subsequent destruction. This mechanism highlights the...
1 May 2024 to 30 Sep 2026
Cell and gene therapies are promising treatments for several unmet medical needs. Most of these therapies rely on viral vectors as the delivery tool for cell modification. HEK-293 cell line is the most used platform for the manufacturing of cell and gene therapy viral vectors that have achieved successful clinical data and regulatory approval for commerci...
1 Jan 2024 to 31 May 2024
Antibody therapeutics are a class of drugs with synthetic antibodies as the active ingredient. They offer highly targeted and effective treatments for a wide range of diseases. The analysis of antibodies during drug development presents significant challenges due to their complexity. First, assessing their binding affinity and specificity necessitates int...
1 Nov 2022 to 31 Mar 2023
The goal of HexagonFab is to unlock the secrets of biomolecules and shed light on how they interact. The protein analysis instrument BOLT created by HexagonFab helps the pharmaceutical industry to develop the medicine of the future, to find the best practice to produce drugs and to ensure their efficacy and safety through convenient and accelerated qualit...
1 Jan 2022 to 31 Mar 2022
The goal of HexagonFab is to unlock the secrets of biomolecules and shed light on how they interact. The tools created by HexagonFab help researchers to develop the medicine of the future, to find the best ways to produce novel biomolecules and to assure that medicine is always safe and efficacious. The current systems used in drug discovery and developme...
1 Jun 2020 to 30 Nov 2020
no public description
1 Feb 2020 to 31 Jan 2021
The influenza burden Each year more than 800'000 people in the UK see their GP for suspected influenza infection and 20'000-30'000 people are admitted to hospitals. Hospitals face the daily risk that incoming patients (110,000 annually in the Emergency Room in Addenbrooke's Hospital in Cambridge 2017/2018) will lead to Influenza outbreaks in the hospital....
1 Apr 2019 to 30 Jun 2019
Each year more than 800'000 people in the UK see their GP for suspected influenza infection and 20-30'000 hospital people are admitted to hospitals. Hospitals face the daily risk that incoming patients (100,000 in the Emergency Room 2017 in Addenbrooke's Hospital in Cambridge) will lead to Influenza outbreaks in the hospital. Indeed, there were more 700 c...
